In Focus: UQ Diamantina Institute

In Focus: UQ Diamantina Institute Learn more about the institutes we support through our In Focus series.

The University of Queensland Diamantina Institute (UQDI) is a modern research facility where clinical and basic science are used to study cancer, immunology and genomic medicine. The Institute has a vibrant community of over 300 researchers, students and support staff.

The Institute takes pride in having delivered many global, world-changing discoveries such as the Discovery, development and release of the world’s first cervical cancer vaccine and the identification of new markers for blood cancer.
Based at the Translational Research Institute (TRI), beside the Princess Alexandra Hospital, UQDI has strong clinical interactions and best in class facilities that enable researchers to be at the forefront of their fields. UQDI’s position within the TRI allows for a much greater collaborative research environment, ensuring our researchers focus their efforts on turning their scientific discoveries into new treatments for diseases including a variety of cancers, arthritis and other autoimmune diseases.
UQDI focuses on bringing scientific discoveries to the patient. The Institute aims to translate research discoveries into the prevention and treatment of major diseases. As part of The University of Queensland’s prestigious Faculty of Medicine, UQDI is committed to making a global difference to health outcomes.
UQDI’s research strengths lie in blood cancer, genomic medicine, immunity and inflammation, immunotherapy as well as skin and skin cancer.

Meet the scientist we've funded at UQ Diamantina Institute

Dr Andrew Moore

Dr Moore is a Paediatric Oncologist at the Lady Cilento Children’s Hospital and Group Leader of the Childhood Leukaemia Research Laboratory at the University of Queensland Diamantina Institute, TRI. He is also Director of the Queensland Children’s Tumour bank, one of only 3 biobanks in Australia dedicated to childhood cancer. After completing his clinical training in Paediatric Oncology in Brisbane, Dr Moore undertook a PhD in cancer drug development at the Institute of Cancer Research, University of London and the Royal Marsden Hospital.
Dr Moore’s clinical and research interests are on acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. His research focuses on understanding the causes of resistance to therapy and relapse, and aims to discover new therapeutic approaches for this devastating disease.

Read more: Personalised disease monitoring in childhood AML.
Donate to research and help find more effective treatments for kids with cancer.